China Grand Pharmaceutical and Healthcare Holdings Limited provided earnings guidance year ended 31 December 2019. It is expected that the consolidated net profit attributable to owners of the Company recorded an increase of not less than 50% as compared to that of the year ended 31 December 2018 (the audited consolidated net profit attributable to owners of the Company for the year ended 31 December 2018 amounted to approximately HKD 712,667,000). The Board considers that the reason for financial results growing in a good shape is mainly attributable to (among other things) the Group's strategy in the development of innovative and barrier medicines has continuously contributed substantive results, and the turnover of the products with competitiveness advantages and high gross profit margin recorded significant growth as compared with 2018, also Shanghai Xudong Haipu Pharmaceutical Co. Ltd. These resulted the Group can maintain a substantial growth in net profit.